ReviewJournal of Alzheimer's disease reports
Prognostic value of baseline plasma p-tau217 for incident cognitive impairment in cognitively unimpaired cohorts: A systematic review and meta-analysis.
Review in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasma phosphorylated tau 217 (p-tau217) is an accessible biomarker of Alzheimer's disease pathology, but its longitudinal association with incident cognitive impairment in cognitively unimpaired adults remains uncertain. Objective: To quantify the prognostic association between baseline plasma p-tau217 and subsequent incident cognitive impairment. Methods: Six databases and two trial registries were searched through July 2026 for longitudinal studies enrolling cognitively unimpaired adults with baseline plasma or serum p-tau217 and subsequent mild cognitive impairment, dementia, composite cognitive impairment, or sustained Clinical Dementia Rating progression. Adjusted hazard ratios (HRs) per 1-SD higher p-tau217 were pooled using random-effects restricted maximum likelihood with Hartung-Knapp inference. Heterogeneity and 95% prediction intervals were estimated. A post hoc sensitivity analysis excluded WHIMS. Results: Six reports representing 16 cohorts were eligible; four reports contributed 13 independent cohort estimates comprising 6856 participants and 1939 events. Higher baseline p-tau217 was associated with greater hazard of incident cognitive impairment (HR 1.64, 95% CI 1.40-1.91; I Conclusions: Higher baseline plasma p-tau217 is a prognostic factor for broadly defined incident cognitive impairment in cognitively unimpaired adults. However, substantial heterogeneity, clinically distinct outcome definitions, and limited independent reports preclude interpreting the pooled HR as Alzheimer-specific progression or individual-level predictive performance. Future studies should prioritize standardized outcomes, assay harmonization, and externally validated absolute-risk models. These findings support evaluation of p-tau217 within multivariable prognostic models and trial-enrichment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.